Over the last two decades, my research program has been focused on antimalarial drug resistance (including P. falciparum and P. vivax parasites) along my different positions in the Institut Pasteur International Network, in Africa (Central African Republic, 2000-2004 and Madagascar, 2005-2008) or in Southeast Asia (Cambodia 2010-2017). I have conducted complementary studies in Madagascar and in Cambodia, based on molecular diagnostic strategies and field-based investigations, with the aims to improve our understanding on the epidemiological features of malaria endemicity and help policy makers to conduct elimination plans. Particularly, studies focused on epidemiologically associations between human host and susceptibility to P. vivax malaria have allowedto to demonstrate that P. vivax in Madagascar is causing blood stage infection and clinical disease in Duffy-negative individuals. In Cambodia, more recently, my research on P. falciparum drug resistance have been focused on the development of new in vitro assays to better characterize P. falciparum isolates resistant to artemisinin or to piperaquine. My major achievements have been to demonstrate that mutations in the propeller domain of a Kelch gene located on chromosome 13 (K13) and amplification of plasmepsin 2-3 genes are major determinants of artemisinin and piperaquine resistances, respectively. With my colleagues involved in the KARMA project, we have recently provided a worldwide mapping of the K13 polymorphisms.
Since September 2017, I have a new position at Institut Pasteur Paris, as the head of the Malaria Genetic and Resistance Group hosted by the Biology of Host-Parasite Interactions Unit. I have published >150 peer-review articles in international journals (http://publicationslist.org/didier.menard).
Click to view graph
Connections
Click to view timeline
Timeline
About
Transversal Projects
Projects
Former Teams
Publications
Download-
2022Vivax malaria in Duffy-negative patients shows invariably low asexual parasitaemia: implication towards malaria control in Ethiopia., Malar J 2022 Aug; 21(1): 230.
-
2022Human peroxiredoxin 6 is essential for malaria parasites and provides a host-based drug target., Cell Rep 2022 Jun; 39(11): 110923.
-
2022Artesunate-amodiaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Liberia: in vivo efficacy and frequency of molecular markers., Malar J 2022 Apr; 21(1): 134.
-
2021Compensating P. falciparum artemisinin resistance., Cell Host Microbe 2021 12; 29(12): 1732-1734.
-
2021Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria., Malar J 2021 Sep; 20(1): 366.
-
2021Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria., PLoS Negl Trop Dis 2021 Sep; 15(9): e0009690.
-
2021A genetic intervention., Elife 2021 Aug; 10(): .
-
2021Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness., Elife 2021 Jul; 10(): .
-
2021Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea., Malar J 2021 Jun; 20(1): 275.
-
2021Genetic diversity of Plasmodium falciparum populations in three malaria transmission settings in Madagascar., Malar J 2021 May; 20(1): 239.
-
+View full list of publications